Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acro Biomedical CoROCO:6748 +16.57%66 Gross Margin % is 59.33% as of Dec. 2025, which is 5% below its 10-year median of 62.47. GuruFocus rates ROCO:6748 with a GF Score™ of 66/100 and a GF Value™ of NT$32.13 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 732 Biotechnology companies, Acro Biomedical Co ranks worse than 61.48% on this metric.
The historical rank and industry rank for Acro Biomedical Co's Gross Margin % or its related term are showing as below:
ROCO:6748'
s Gross Margin % Range Over the Past 10 Years
Min: 47.55 Med: 62.47 Max: 76.6
Current: 48.43
During the past 8 years, the highestGross Margin % of Acro Biomedical Co was 76.60%. The lowest was 47.55%. And the median was 62.47%.
ROCO:6748's Gross Margin % is ranked worse than 61.48% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs ROCO:6748: 48.43
Acro Biomedical Co had a gross margin of 59.33% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Acro Biomedical Co was 0.60% per year.
Acro Biomedical Co (ROCO:6748) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Acro Biomedical Co had a gross margin of 59.33% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Acro Biomedical Co Gross Margin % Related Terms
Acro Biomedical Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Acro Biomedical Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6748 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Acro Biomedical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acro Biomedical Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acro Biomedical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Acro Biomedical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Acro Biomedical Co (ROCO:6748) has a Gross Margin % of 59.33% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Acro Biomedical Co and its competitors. This is near median its historical median of 62.47. Over the past decade, Acro Biomedical Co's Gross Margin % has ranged from 47.55 to 76.60. According to the industry distribution chart, Acro Biomedical Co ranks #450 out of 732 companies in the Biotechnology industry, placing it in the top 61.5%.
Is Acro Biomedical Co's Gross Margin % too high?
Acro Biomedical Co's current Gross Margin % of 59.33% is near median its 10-year median of 62.47. Over the past 10 years, this metric has ranged from a low of 47.55 to a high of 76.60. The Biotechnology industry median Gross Margin % is 60.91. Acro Biomedical Co's value of 59.33% is 2.6% below this industry median. Based on the distribution chart, Acro Biomedical Co ranks #450 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Acro Biomedical Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acro Biomedical Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acro Biomedical Co ranks #450 out of 732 companies for Gross Margin %. This places Acro Biomedical Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Acro Biomedical Co's value of 59.33% is 2.6% below this benchmark. Historically, Acro Biomedical Co's own Gross Margin % has ranged from 47.55 to 76.60 over the past decade. While the company's 10-year median is 62.47 vs. the industry median of 60.91, Acro Biomedical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acro Biomedical Co's current Gross Margin % of 59.33% is 2.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Acro Biomedical Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acro Biomedical Co's current Gross Margin % is 59.33%, which is near median its own 10-year median of 62.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Acro Biomedical Co (ROCO:6748) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$32.13, compared to a current price of NT$295.50 — trading 819.7% above its estimated fair value. The current Gross Margin % is 59.33%, which is near median its 10-year median of 62.47 and 2.6% below the Biotechnology industry median of 60.91. Acro Biomedical Co's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Acro Biomedical Co (ROCO:6748), the current Gross Margin % is 59.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acro Biomedical Co (ROCO:6748) Overvalued in 2026?
Based on GuruFocus' analysis, Acro Biomedical Co stock appears to be overvalued.
The current stock price of NT$295.50 is trading 819.7% above its estimated GF Value™ of NT$32.13.
GuruFocus considers Acro Biomedical Co to be Significantly Overvalued.
Key valuation signals for ROCO:6748:
Gross Margin %: 59.33% (near median its 10-year median of 62.47)
GF Value™: NT$32.13 vs. price of NT$295.50 (819.7% above fair value)
Industry Position: 2.6% below the Biotechnology median (#450 of 732)
No single metric tells the full story. See the ROCO:6748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acro Biomedical Co Ltd is a company whose technical team integrates the Research and development capabilities of Taiwan's major scientific research units and medical centers to jointly develop equipment for repairing organs and tissues in various parts of the human body. It mainly focuses on orthopedics, dentistry, cardiovascular specialists, ophthalmology, surgery, wound care, Medical equipment used in sports injuries and other specialties.
66GF Score
Get the complete analysis for ROCO:6748
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6748 has been successfully added to your 
